Silva, M. Catarina http://orcid.org/0000-0001-5421-6673
Nandi, Ghata A. http://orcid.org/0000-0001-7170-8709
Tentarelli, Sharon
Gurrell, Ian K.
Jamier, Tanguy
Lucente, Diane
Dickerson, Bradford C.
Brown, Dean G.
Brandon, Nicholas J.
Haggarty, Stephen J. http://orcid.org/0000-0002-7872-168X
Article History
Received: 23 October 2019
Accepted: 30 May 2020
First Online: 26 June 2020
Competing interests
: At the time of this study, S.T., I.K.G., T.J., D.G.B. and N.J.B. were fulltime employees by and shareholders in AstraZeneca. S.J.H. is a member of the SAB and equity holder in Rodin Therapeutics, Psy Therapeutics, Frequency Therapeutics, and Souvien Therapeutics, none of whom were involved in this study. S.J.H. has received consulting or speaking fees from Sunovion, Biogen, AstraZeneca, Amgen, and Merck. B.C.D. is a consultant with Arkuda, Axovant, Biogen, Lilly, Merck, Novartis and Wave Life Sciences; and has editorial duties with honoraria with Elsevier. B.C.D. also received royalties from Oxford University Press and Cambridge University Press. None of these entities were involved in this study.